

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DA	TE FIRST NAMED INVENT	OR ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/088,598	03/21/20	2 Akio Yamanc	2002-0401Λ	6872		
513	7590 10	/04/2004	EXA	EXAMINER		
		ONACK, L.L.P.	SAKELAR	SAKELARIS, SALLY A		
2033 K STR SUITE 800	EET N. W.		ART UNIT	PAPER NUMBER		
	TON, DC 2000	5-1021	1634	1634		
			DATE MAILED: 10/04/20	004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application I		Applicant(s)				
		10.					
Office Action Summary	10/088,598		YAMANE, AKIO				
Office Action Summary	Examiner		Art Unit				
	Sally A Sakel		1634				
The MAILING DATE of this communication app Period for Reply	ears on the co	ver sneet with the	correspondence ad	aress			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, I y within the statutory will apply and will ex	nowever, may a reply be till minimum of thirty (30) da pire SIX (6) MONTHS from on to become ABANDON	mely filed  ys will be considered timel  n the mailing date of this co  ED (35 U.S.C. § 133).	y. ommunication.			
Status							
1)⊠ Responsive to communication(s) filed on 22 Ju	uly 2004.						
	<u>_</u>						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) Claim(s) 1-3 and 5-9 is/are pending in the appl 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) 1-3 and 5-9 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o	wn from consi						
Application Papers							
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicated and accomplicated and any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	epted or b)  drawing(s) be h tion is required i	eld in abeyance. Se f the drawing(s) is ob	ee 37 CFR 1.85(a). ojected to. See 37 CI				
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) ☐ All b) Some * c) ☐ None of:  1. ☐ Certified copies of the priority documents have been received.  2. ☐ Certified copies of the priority documents have been received in Application No  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) 5) 6)	Paper No(s)/Mail D Notice of Informal I		O-152)			

#### DETAILED ACTION

This action is written in response to applicant's correspondence submitted 7/22/2004. Claims 1 and 5 have been amended, claim 4 has been canceled, and no claims have been added. Claims 1-3 and 5-9 are pending. Applicant's amendments and arguments have been thoroughly reviewed, but are not persuasive for the reasons that follow. Any rejections not reiterated in this action have been withdrawn as necessitated by applicant's amendments to the claims. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. **This action is FINAL.** 

### **Priority**

Acknowledgement of claim to foreign priority of Japanese Application, 11/268745, filed 9/22/1999 under 35 U.S.C. 119(a)-(d) has been made, however applicant should note that the certified copy and translation of this foreign priority document has not yet been received and as a result the claim to foreign priority under the same has not yet been granted.

#### Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 1. Claims 1-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Livak et al.(US Patent 5,723,591)

Art Unit: 1634

With regard to claim 1, Livak et al. teach a probe comprising a nucleic acid carrying a labeling substance that releases energy and an energy-absorbing substance capable of absorbing the energy(quencher) released from the labeling substance, wherein energy transfer from the labeling substance to the energy-absorbing substance is intercepted by the hybridization of the probe with a target nucleic acid, in their teaching of an oligonucleotide probe "which includes a fluorescent reporter molecule and a quencher molecule capable of quenching the fluorescence of the reporter molecule" (abstract and for example Figure 1 and claim 1). The reference goes on to teach that "the oligonucleotide probe is constructed such that the probe exists in at least one single-stranded conformation when unhybridized where the quencher molecule is near enough to the reporter molecule to quench the fluorescence of the reporter molecule". "The oligonucleotide probe also exists in at least one conformation when hybridized to a target polynucleotide where the quencher molecule is not positioned close enough to the reporter molecule to quench the fluorescence of the reporter molecule" (Abstract).

With regard to claim 2, Livak et al. teach that "the reporter molecule and quencher molecule are positioned on the probe sufficiently close to each other such that whenever the reporter molecule is excited, the energy of the excited state nonradiatively transfers to the quencher molecule where it either dissipates nonradiatively or is emitted at a different emission frequency than that of the reporter molecule" (Col. 3 lines 3-8).

With regard to claim 3, Livak et al. teach that the labeling substance is a fluorescent substance and "may be selected from xanthene dyes, including fluoresceins, and rhodamine dyes" (Col. 11 lines 22-23).

Art Unit: 1634

With regard to claims 4 and 5 Livak et al. teach that the energy absorbing(quencher) is an intercalator or a substance which specifically binds to a double stranded nucleic acid, in Col. 11 in their teachings of exemplary reporter-quencher pairs and dyes including acridines like acridine orange, "pyrenes and the like"(lines 33-35).

With regard to claim 6, Livak et al. teach that the labeling substance "may be selected from xanthene dyes, including fluoresceins, and rhodamine dyes" (Col. 11 lines 22-23). While Livak et al. also teach that the energy absorbing (quencher) may be selected from another group of fluorescent compounds including acridines like acridine orange, "pyrenes and the like" (lines 33-35).

With regard to claim 7, Livak et al. teach "according to one embodiment of the method, the hybridization probe is immobilized on a solid support" (Col. 8, lines 38-50). "The oligonucleotide probe is contacted with a sample of nucleic acids under conditions favorable for hybridization". "The fluorescence signal of the reporter molecule is measured before and after being contacted with the sample. Since the reporter molecule on the probe exhibits a greater fluorescence signal when hybridized to a target sequence, an increase in the fluorescence signal after the probe is contacted with the sample indicates the hybridization of the probe to target sequences in the sample". "Immobilization of the hybridization probe to the solid support enables the target sequence hybridized to the probe to be readily isolated from the sample" (Col. 8 and claim 16).

With regard to claims 8 and 9, as stated above, Livak et al. teach that "the present invention relates to the use of the oligonucleotide probe as a hybridization probe to detect target polynucleotides" (Col. 5 lines 39-60). Further that "quantification of the change in fluorescence

Application/Control Number: 10/088,598 Page 5

Art Unit: 1634

intensity as a result of the probe being contacted with the sample can be used to quantify the amount of target sequences present in the sample" (Col. 5 lines 55-58).

Art Unit: 1634

## Response to Arguments

Applicant's arguments filed 7/22/2004 have been fully considered but they are not persuasive. Applicant first argues that Livak et al. "fails to disclose or suggest each and every element of the claimed invention, namely a probe comprising an intercalator or an energyabsorbing substance that specifically binds a double stranded nucleic acid due to the hybridization of the probe with a target nucleic acid whereby the energy transfer from the labeling substance to the energy-absorbing substance is intercepted resulting in no quenching" (6/30/04 response pg. 5). Applicant should note that this limitation is not recited in their claims as they are presently written. Limitations in applicant's arguments, specification etc cannot be read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Furthermore, without a requirement for the interception to result in no quenching, or a requirement for a hybridization step to necessitate the interception, the art will be applied as broadly as the claims are written. The courts have stated that claims must be given their broadest reasonable interpretation consistent with the specification In re Morris, 127 F.3d 1048, 1054-55, 44 USPO2d 1023, 1027-28 (Fed. Cir. 1997); In re Prater, 415 F.2d 1393, 1404-05, 162 USPQ 541, 550-551 (CCPA 1969); and *In re Zletz*, 893 F.2d 319, 321-22, 13 USPQ2d 1320, 1322 (Fed. Cir. 1989) (see MPEP 2111). As such, one interpretation of the claim is that the quencher moiety is intercepting the energy transfer from the labeling substance. It should further be noted that the requirement for an intercalator is made in the alternative and as such is not a required limitation to be taught in the cited art.

Next, applicant argues that in the specification on page 5, lines 3-9, discusses the fact that "the energy transfer from the labeling substance to the energy-absorbing substance or intercalator

Art Unit: 1634

is intercepted by the hybridization of the probe with a target nucleic acid". "This, in turn, releases the light from the labeling substance" and further that reference to the specification at page 8, lines 11-29 and also in Figure 1 teach the embodiment of their invention that is not taught by the prior art. However, it is maintained that limitations of the specification shall not be read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). It should be further noted that if applicants do amend their claims to include, thus far unexamined limitations, further search and examination would be required.

Lastly applicant argues that Livak "neither discloses nor suggests that a quencher molecule binds to or intercalates to a double-stranded nucleic acid or that the fluorescence of the reporter molecule in thereby unquenched". However, as stated above this limitation is not in the claims as presently written and furthermore there is no requirement in the claim for the ordered sequential steps of hybridization, intercepting, and quenching to occur which applicant argues in their response. Furthermore, the fact that the Livak probe includes a conformational change is irrelevant considering the claim does not preclude such an embodiment and further that Livak is able to anticipate the limitations of the claims as presently written.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

MONTHS of the mailing date of this final action and the advisory action is not mailed until after

Art Unit: 1634

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

however, will the statutory period for reply expire later than SIX MONTHS from the date of this

final action.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Sally A Sakelaris whose telephone number is 571-272-0748. The

examiner can normally be reached on M-Fri, 9-6:30 1st Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the

organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sally Sakelaris

garay sm

9/30/04

SUPERVISORY PATIENT EXAMINER

TECHNOLOGY CENTER 1800